Published in Inflammatory Bowel Diseases (2024)
Collaborator: Takeda Pharmaceuticals International AG
Authors: Gionata Fiorino, Nawal Bent-Ennakhil, Pasquale Varriale, Fiona Braegger, Eveline Hoefkens
This study explored patients’ preferences for treatment attributes in Crohn’s disease or ulcerative colitis, such as subcutaneous/intravenous drug administration and adverse effects. Patients’ preferences highlighted the importance of personalized care and shared decision making to maximize treatment benefits.